CA3093715A1 - Synthetic rig-i-like receptor agonists - Google Patents

Synthetic rig-i-like receptor agonists Download PDF

Info

Publication number
CA3093715A1
CA3093715A1 CA3093715A CA3093715A CA3093715A1 CA 3093715 A1 CA3093715 A1 CA 3093715A1 CA 3093715 A CA3093715 A CA 3093715A CA 3093715 A CA3093715 A CA 3093715A CA 3093715 A1 CA3093715 A1 CA 3093715A1
Authority
CA
Canada
Prior art keywords
agonist
inosine
seq
cytidine
rlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3093715A
Other languages
English (en)
French (fr)
Inventor
Arthur M. Krieg
Aaron Jay MORRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Checkmate Pharmaceuticals Inc
Original Assignee
Checkmate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkmate Pharmaceuticals Inc filed Critical Checkmate Pharmaceuticals Inc
Publication of CA3093715A1 publication Critical patent/CA3093715A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3093715A 2018-04-19 2019-04-19 Synthetic rig-i-like receptor agonists Pending CA3093715A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659999P 2018-04-19 2018-04-19
US62/659,999 2018-04-19
PCT/US2019/028343 WO2019204743A1 (en) 2018-04-19 2019-04-19 Synthetic rig-i-like receptor agonists

Publications (1)

Publication Number Publication Date
CA3093715A1 true CA3093715A1 (en) 2019-10-24

Family

ID=66647446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3093715A Pending CA3093715A1 (en) 2018-04-19 2019-04-19 Synthetic rig-i-like receptor agonists

Country Status (7)

Country Link
US (3) US10907161B2 (enExample)
EP (1) EP3781689A1 (enExample)
JP (3) JP7366057B2 (enExample)
CN (2) CN119286871A (enExample)
AU (3) AU2019255370B2 (enExample)
CA (1) CA3093715A1 (enExample)
WO (1) WO2019204743A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115969971A (zh) * 2022-11-24 2023-04-18 珠海恩科生物科技有限公司 组合物在制备治疗肿瘤的药物中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
EP3863675A4 (en) * 2018-10-09 2023-09-06 Yale University RIG-I AGONISTS AND METHODS OF USE THEREOF
JP7707161B2 (ja) * 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
US11786545B2 (en) * 2020-12-09 2023-10-17 Yale University Compositions and methods for treating SARS-CoV-2 infection
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
CN119371516B (zh) * 2024-11-01 2025-08-12 复旦大学 一种抗肿瘤的短肽、药物组合物及其应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
FR2693813B1 (fr) 1992-07-20 1994-08-19 Commissariat Energie Atomique Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP0880046B1 (en) 1996-10-14 2010-03-17 Seiko Epson Corporation Method of manufacturing progressive multifocal lens
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
DE60122300T2 (de) 2000-04-07 2007-08-30 The University Of Leeds Hepatitis b kernprotein fusionsproteine
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU2001266163B2 (en) 2000-06-22 2006-07-13 Celltech Pharmaceticals Limited Modification of hepatitis b core antigen
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
DE10201743C2 (de) 2002-01-18 2003-12-18 Aesculap Ag & Co Kg Intramedulläres Osteosyntheseimplantat
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
ATE390205T1 (de) 2002-12-10 2008-04-15 Haldor Topsoe As Verfahren zur katalytischen dehydrierung und katalysator dafür
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8003619B2 (en) 2004-12-09 2011-08-23 Alnylam Pharmaceuticals, Inc. Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110184045A1 (en) 2008-06-30 2011-07-28 Gunther Hartmann Silencng and rig-i activation by dual function oligonucleotides
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
CA2735860A1 (en) 2008-09-02 2010-03-11 Alnylam Pharmaceuticals, Inc. Synthetic methods and derivatives of triphosphate oligonucleotides
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2013064584A1 (en) 2011-10-31 2013-05-10 Riboxx Gmbh Double-stranded RNA for immunostimulation
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013097965A1 (en) 2011-12-30 2013-07-04 Riboxx Gmbh Triphosphate-containing double-stranded rna for immunostimulation
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US20140287023A1 (en) 2013-02-11 2014-09-25 Mcgill University 5'-triphosphate oligoribonucleotides
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014159990A1 (en) * 2013-03-13 2014-10-02 Yale University Interferon production using short rna duplexes
WO2014169049A1 (en) * 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
WO2015038746A1 (en) 2013-09-11 2015-03-19 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expression
WO2015091578A1 (en) 2013-12-16 2015-06-25 Riboxx Gmbh Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CA2953336C (en) 2014-07-15 2023-03-21 Drifire, Llc Lightweight, dual hazard fabrics
EP3172324A4 (en) 2014-07-18 2018-04-25 Oregon Health & Science University 5'-triphosphate oligoribonucleotides
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
WO2017121494A1 (en) 2016-01-15 2017-07-20 Riboxx Gmbh 5'-triphosphated short immunostimulatory nucleotides, oligonucleotides and polynucleotides
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
CA3061077A1 (en) 2016-04-26 2017-11-02 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue
WO2017221076A1 (en) 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11382966B2 (en) * 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
US10736957B2 (en) * 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
CA3086040A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
CN112369115B (zh) 2018-05-08 2024-11-08 瑞典爱立信有限公司 用于实现业务管理的方法和节点
EP3810151B1 (en) * 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
JP7707161B2 (ja) 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
CN115376873A (zh) 2021-05-18 2022-11-22 江苏鲁汶仪器有限公司 离子源装置及其使用方法和真空处理系统

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115969971A (zh) * 2022-11-24 2023-04-18 珠海恩科生物科技有限公司 组合物在制备治疗肿瘤的药物中的应用
CN115969971B (zh) * 2022-11-24 2023-08-18 珠海恩科生物科技有限公司 组合物在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
CN112105733B (zh) 2024-10-29
JP7366057B2 (ja) 2023-10-20
AU2019255370A1 (en) 2020-09-17
US20200063141A1 (en) 2020-02-27
US12123003B2 (en) 2024-10-22
JP7847568B2 (ja) 2026-04-17
US20210207148A1 (en) 2021-07-08
AU2019255370B2 (en) 2023-11-02
EP3781689A1 (en) 2021-02-24
US20240368607A1 (en) 2024-11-07
CN112105733A (zh) 2020-12-18
AU2023229532B2 (en) 2024-09-26
WO2019204743A1 (en) 2019-10-24
CN119286871A (zh) 2025-01-10
US10907161B2 (en) 2021-02-02
AU2023229532A1 (en) 2023-09-28
AU2024287196A1 (en) 2025-01-23
JP2021521780A (ja) 2021-08-30
JP2023158048A (ja) 2023-10-26
JP2025120300A (ja) 2025-08-15

Similar Documents

Publication Publication Date Title
AU2023229532B2 (en) Synthetic rig-i-like receptor agonists
US11596609B2 (en) Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
JP2020529977A (ja) 増殖性疾患及び感染症の処置のためのサイトカイン抱合体
JP2025138811A (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
EP4719437A1 (en) Connector modified synthetic rig-i agonists and methods of using the same
McCormick RIPK1 down-regulation promotes tumor progression while enhancing the apoptotic response to TLR3 ligand in head and neck squamous cell carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250902